Rudi Mueller-Walz

Title: Rudi Mueller-Walz: Innovating Medicinal Aerosol Formulations

Introduction: Rudi Mueller-Walz is a notable inventor based in Schopfheim, Germany, recognized for his contributions to the field of medicinal aerosol formulations. With a total of six patents to his name, he has made significant strides in improving drug delivery systems through innovative formulations.

Latest Patents: Among Rudi's latest inventions is a groundbreaking medicinal aerosol suspension formulation designed for Metered Dose Inhalers (MDIs). This formulation comprises a micronized β-agonist, a micronized corticosteroid, a sub-therapeutic quantity of a moisture-scavenger excipient, and an HFA propellant. The unique combination and relative amounts of these components allow the creation of floccules that maintain a density similar to that of the HFA propellant. Another notable patent involves a method for producing a highly stable pharmaceutical aerosol suspension containing formoterol fumarate dihydrate, a steroid, a propellant, and ethanol. This method optimizes the drying process of formoterol to achieve a specific water content, ensuring stability in the final product.

Career Highlights: Rudi Mueller-Walz currently works at Jagotec AG, a company renowned for its focus on innovative pharmaceutical solutions. His work at Jagotec AG has been pivotal in advancing aerosol technology, addressing the critical needs of patients requiring effective inhalation therapies.

Collaborations: Throughout his career, Rudi has collaborated with esteemed colleagues such as Roland Steiner and Lise-Marie Fueg. These partnerships have fostered a creative environment surrounding the development of new pharmaceutical formulations, pushing the boundaries of what's possible in medicinal aerosol therapies.

Conclusion: Rudi Mueller-Walz's contributions to the field of medicinal aerosol formulations underscore his role as an innovator in pharmaceutical technology. With a strong track record of patents and collaborative efforts, Rudi continues to influence the future of inhalation therapies, improving the delivery of critical medications to patients worldwide.